Skip to main content
Equibles

AKUMS · Akums Drugs and Pharmaceuticals Limited · Documents

Use AKUMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AKUMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
741.05 INR -8.85 (-1.18%) At close · Nov 13
Rebalance outlook locked
Market Cap
116.64B INR
Shares
157.39M
Volume · Nov 13 130.41K Avg daily vol (3M) 302.16K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 3, 2026
2026
Nov 3
Earnings call
Revenue rises 31.9%, EBITDA rises 106% in Q2 FY27

ACOM Drugs and Pharmaceuticals Limited reported consolidated revenue of 1342 crores, up 31.9% year-on-year, and EBITDA of 195 crores, up 106%, for the quarter ended 30th September, 2026, as CDMO volumes grew more than 20%.

5 source passages
I am Ankit Jain, and I head Investor Relations at ACOM Drugs and Pharmaceuticals Limited. Welcome, everyone, to ACOM's Q2 FY27 earnings call. I am pleased to present the financial highlights for the quarter, 30th September, 2026. Revenue on a consolidated basis stood at 1342 crores, an increase of 31.9% year-on-year. EBITDA for the quarter stood at a healthy 195 crores, a multi-fold increase of 106% year-on-year. The CDMO business achieved a volume growth of more than 20% on September MET basis, showcasing increasing penetration of our offering within the India pharma market. Open the document at this passage
Showing 1–3 of 3 documents